EpCAM-Expressing Circulating Tumor Cells in Colorectal Cancer

Nicolazzo, Chiara; Raimondi, Cristina; Francescangeli, Federica; Ceccarelli, Simona; Trenta, Patrizia; Magri, Valentina; Marchese, Cinzia; Zeuner, Ann; Gradilone, Angela; Gazzaniga, Paola

doi:10.5301/ijbm.5000284

Cited by 32 publications

(34 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EpCAM low CTCs was not signi cantly associated with prognosis of patients, contrary to the presence of ≥5 EpCAM high . Additionally, previous study also indicated that EpCAM high CTCs from colorectal cancer approximately account for 89% (39), which indicates the numbers of CTCs detected with CellSearch system were more than the missed EpCAM low CTCs, and correspondingly the signi cance of EpCAM high CTCs were higher. Collectively, these studies all suggested that although CTCs with a mesenchymal phenotype may not be detected by the CellSearch system, obvious signi cance of EpCAM low CTCs in predicating prognosis in cancer patients was not indicated.…”

Section: Discussionmentioning

confidence: 88%

Prognostic Value of Circulating Tumour Cells detected with the CellSearch System in Esophageal Cancer Patients: A Systematic Review and Meta-Analysis

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Esophageal carcinoma (EC) is the seventh-most prevalent tumor in the world, which is still one of the primary causes of tumor-related death. Identifying noteworthy biomarkers for EC is particularly significant in guiding effective treatment. Recently, circulating tumor cells (CTCs) in peripheral blood (PB) were intensively discussed as prognostic markers in patients with EC. However, an ongoing controversy still exists regarding the prognostic significance of CTCs determined by the CellSearch system in EC sufferers. This meta-analysis was designed to approach this topic. Methods: We systematically conducted searches using PubMed, Medline, Web of Science and the Cochrane Library for relevant studies, which were published through February 20, 2020. Using the random-effects model, our study was performed in Review Manager software, with odds ratios (ORs), risk ratios (RRs), hazard ratios (HRs) and 95% confidence intervals (CIs) as the effect values. Results: Totally 7 articles were finally included in this study. For clinicopathological characteristics, the pooled results on TNM stage indicated that the III/IV group had higher rate of CTCs compared with the I/II group (OR=1.36, 95% CI: 0.68-2.71, I2=0%). Incidence of CTCs was higher in patients with T3/T4 stage (OR=2.92, 95% CI: 1.31-6.51, I2=0%) and distant metastasis group (OR=5.18, 95% CI: 2.38-11.25, I2=0%) compared to patients with T1/T2 stage or non-metastatic group. The pooled analysis revealed that CTC positivity detected in EC patients was correlated with poor overall survival (OS) (HR=2.83, 95% CI:1.99-4.03, I2=0%) and relapse-free survival (RFS) (HR=4.71, 95% CI:2.73-8.13, I2=0%). When pooling the estimated RR, a poor therapeutic response to chemoradiotherapy was discovered in patients with CTC positivity (RR=1.99, 95% CI:1.73-2.29, I2=60%). Conclusions: In summary, our meta-analysis demonstrated that CTCs positivity determined by the CellSearch system are correlated with the prognosis of EC patients and might indicate a poor therapeutic response to chemotherapy in EC patients.

show abstract

Section: Discussionmentioning

confidence: 88%

Prognostic Value of Circulating Tumour Cells detected with the CellSearch System in Esophageal Cancer Patients: A Systematic Review and Meta-Analysis

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Depletion of leukocytes. Leukocyte depletion was performed using Dynabeads CD45 (Invitrogen; Thermo Fisher Scientific, Inc.) in order to enrich CTCs from whole blood, following the manufacturer's instructions, as previously described (33). Each blood sample was incubated with Dynabeads (Invitrogen; Thermo Fisher Scientific, Inc.) for 30 min at 2˚C with gentle tilting rotation.…”

Section: Methodsmentioning

confidence: 99%

Detection of circulating tumor cells in patients with laryngeal cancer using ScreenCell: Comparative pre- and post-operative analysis and association with prognosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

The presence of circulating tumor cells (CTCs) in the blood of patients with metastatic breast, colorectal and prostate cancer have been widely investigated; however, few studies have examined CTCs in patients with laryngeal cancer. The present pilot study aimed to detect pre-and postoperative CTCs in the blood of patients with laryngeal cancer and evaluate the association with prognosis. Eight patients with laryngeal squamous cell carcinoma (LSCC) at stage III were included in the present study and underwent total or subtotal laryngectomy and radical bilateral neck lymph node dissection. Blood samples were collected from all patients before and after surgery at different time-points. The following processing steps were followed; preoperative blood sampling, surgery, postoperative blood sampling at 3, 6 and 12 month follow-ups, and prognostic association analysis. CTCs were retained on ScreenCell filters for cytological characterization. The presence of CTCs was associated with a less favorable prognosis, whereas a decrease of CTCs in the postoperative sampling was observed in patients who exhibited an improved therapeutic response. The results of the present pilot study revealed a possible association between the presence of CTCs and a less favorable prognosis in patients with LSCC; therefore, these preliminary findings may encourage further research into the incorporation of a liquid biopsy in the management of LSCC, as this may help identify patients with occult metastatic disease earlier and in a non-invasive manner. In addition, this approach may represent novel independent prognostic factor for use in the clinical evaluation of patients with LSCC.

show abstract

“…53 Quantification of CTCs has been validated for colorectal cancer prognosis, [54][55][56] and increasingly sensitive approaches are being developed for CTC detection in patients with colorectal cancer. 57,58 It is anticipated that such techniques may be used for more sophisticated analysis based on specific markers, such as detection of the KRAS mutation in peripheral blood CTCs, which has been associated with response to cetuximab plus chemotherapy, 59 or FAM172A expression in mesenchymal CTCs, which may be predictive of high-risk stage II colorectal cancer. 60 CTC count has been reported to be predictive of metastasis in patients with gastric cancer, 54 which is a particularly aggressive cancer that is common in Asia, Eastern Europe, and Central and South America.…”

Section: Ctcs and Gastrointestinal Tract Cancersmentioning

confidence: 99%

“…It is thought that monitoring for CTCs in patients with early‐stage colorectal cancer before and after surgery could help to identify patients who are at risk of disease recurrence and therefore are likely to benefit from adjuvant therapy . Quantification of CTCs has been validated for colorectal cancer prognosis, and increasingly sensitive approaches are being developed for CTC detection in patients with colorectal cancer . It is anticipated that such techniques may be used for more sophisticated analysis based on specific markers, such as detection of the KRAS mutation in peripheral blood CTCs, which has been associated with response to cetuximab plus chemotherapy, or FAM172A expression in mesenchymal CTCs, which may be predictive of high‐risk stage II colorectal cancer …”

Section: Introductionmentioning

confidence: 99%

Current progress in the clinical use of circulating tumor cells as prognostic biomarkers

Jin

Chen

Lan³

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

The process of metastasis is characterized by the shedding of tumor cells into the bloodstream, where they are transported to other parts of the body to seed new tumors. These cells, known as circulating tumor cells (CTCs), have the potential to reveal much about an individual cancer case, and theoretically can aid in the prediction of outcomes and design of precision treatments. Recent advances in technology now allow for the robust and reproducible characterization of CTCs from a simple blood draw. Both the number of circulating cells and important molecular characteristics correlated with clinical phenotypes such as drug resistance can be obtained and used for real‐time prognostic analysis. Molecular characterization can provide a snapshot of the activity of the main tumor (serving as a “liquid biopsy”) and early warnings concerning changes such as the development of resistance, and aid in predicting the efficacy of different therapeutic approaches for treatment optimization. Herein, the authors review the current clinical use of CTCs as prognostic biomarkers for several different cancers. The quantification of CTCs can lead to more accurate staging and decision making regarding options such as adjuvant chemotherapy.

show abstract

EpCAM-Expressing Circulating Tumor Cells in Colorectal Cancer

Abstract: This is the first demonstration that the low sensitivity of CellSearch® to detect CTCs in colorectal cancer patients is not due to the lack of EpCAM.

Cited by 32 publications

References 20 publications

Prognostic Value of Circulating Tumour Cells detected with the CellSearch System in Esophageal Cancer Patients: A Systematic Review and Meta-Analysis

Prognostic Value of Circulating Tumour Cells detected with the CellSearch System in Esophageal Cancer Patients: A Systematic Review and Meta-Analysis

Detection of circulating tumor cells in patients with laryngeal cancer using ScreenCell: Comparative pre- and post-operative analysis and association with prognosis

Current progress in the clinical use of circulating tumor cells as prognostic biomarkers

Contact Info

Product

Resources

About